Merck stock dipped more than 4% in morning trading

Tiger Newspress2021-11-29

Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.

Disappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.

Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.

“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.

Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • Huatkor
    2021-11-30
    Huatkor
    Don’t worry. It is a good company even without the covid drug.  
  • TSY123
    2021-11-30
    TSY123
    Ok
  • Juanlee
    2021-11-30
    Juanlee
    Merck pill was reported to have a lower effectiveness than announced. 
  • ArcherWG
    2021-11-30
    ArcherWG
    👌🏻 
  • ShenGY
    2021-11-30
    ShenGY
    Sad
  • MengKeng
    2021-11-30
    MengKeng
    It will be a good time for us to buy, let's monitor and then buy low, sell high. Haha
发表看法
18